Genetic and molecular biology of breast cancer among Iranian patients

Meysam Moghbeli*

Abstract

Abstract: Background, Breast cancer (BC) is one of the leading causes of cancer related deaths in Iran. This high ratio of mortality had a rising trend during the recent years which is probably associated with late diagnosis. Main body: Therefore it is critical to define a unique panel of genetic markers for the early detection among our population. In present review we summarized all of the reported significant genetic markers among Iranian BC patients for the first time, which are categorized based on their cellular functions. Conclusions: This review paves the way of introducing a unique ethnic specific panel of diagnostic markers among Iranian BC patients. Indeed, this review can also clarify the genetic and molecular bases of BC progression among Iranians. Keywords: Breast cancer, Diagnosis, Marker, Prognosis, Genetic, Risk factor

Background

Cancer is the second and third leading cause of deaths in developed and developing countries, respectively [1]. The China, India, and Japan with 59.7% of Asian breast cancer (BC) cases have the highest incidences in Asia [2]. BC is the most common cancer among Iranian females with mean age of between 46 and 49 years old [3]. Unfortunately, it has been shown that the BC mortality rate had a noticeable raising trend in 1990 to 2010 from 0.96 to 4.33 per 100,000 cases [4]. There is a variation about the BC incidence based on geographical districts in Iran in which the central provinces such as Tehran and Isfahan has the highest incidences [5]. Although, Iran is among the low incidence countries in the case of BC, the Iranian patients have lower ages and advanced stage tumors in comparison with another patients in western countries [6]. There are various BC risk factors which can be categorized as genetic and non-genetic. The non-genetic factors are age, life style, early menarche, late menopause, family history, weight, smoking, diet, socioeconomic condition, and air pollution. Age of diagnosis is about 40–50 years in Asian and African patients whereas it is about 60–70 years in Western countries [7, 8]. Ethnic is also important in age of diagnosis in which the black women have lower ages in comparison with the white women (58 vs. 62 years) [9]. Early Menarche/Late Menopause also increases the risk of breast cancer. Delayed pregnancy and decreased period of breastfeeding are also associated with elevated BC risk. Smoking before the menopause increases the risk of BC. There is also a direct correlation between alcohol consumption and BC risk. A regular physical activity and fruits and vegetables consumptions also decreases the BC risk. In the case of genetic risk factors, the BRCA1 and BRCA 2 mutations are among the main factors which are reported and involved in BC [10, 11]. Beside the BRCA family, the variety of genes are also reported during BC progression such as p53 and PTEN tumor suppressors [12, 13]. Members of DNA repair system and cell cycle regulators such as ATM, CHEK2, NBN, PALB2, and RAD50 are also correlated with risk of BC [14]. Late diagnosis in advanced stages of tumor is one of the main reason of high mortality among the BC patients. Therefore, finding new diagnostic markers will improve the early detection and better management of BC among patients. Regarding the differences between populations in the case of genetic factors, it is required to
introduce a population specific panel of genetic markers for every population. Despite various studies about the role of different genes in BC progression among Iranians, there is not still any unique panel of markers for the early detection among Iranian patients. Therefore, for the first time in the present study we summarized the significant genetic markers which are reported until now among the Iranian BC patients (Table 1). We categorized these reported markers in different cellular processes based on their cellular functions (Fig. 1).

Main text

Non coding RNAs and epigenetic modifications

MiRNAs as short non-coding RNAs can regulate gene expression post-transcriptionally through 3-UTR in the target mRNAs which are involved in various cellular functions including apoptosis and cell proliferation [15]. MiRNAs polymorphisms can change the function of miRNAs through modulation of their expression, processing, or binding sequences [16]. It has been observed that there was a significant correlation between rs1134527 variant in miR-218-2 and rs384262 variant in miR-301b and higher risk of BC among a sub population of Iranian patients [17]. SOX2 self renewal factor is one of the targets of miR-140 and miR-140/SOX2 interaction can be associated with cell survival in BC [18]. Another group also evaluated the serum levels of miR-140-3p expression in Iranian BC patients compared with healthy cases. They showed significant miR-140-3p over expression in BC in comparison with the normal cases. Moreover, there was a correlation between mir-140-3p expression and age, in which the premenopausal and ≤ 48 years old female with BC have shown mir-140-3p over expression. They introduced this marker as a diagnostic factor in premenopausal and in ≤ 48 years old females with BC [19]. BRCA1/BRCA2 are the targets of MiR-146a. It has been shown that the mir-146a is involved in BC. Moreover, there was a significant correlation between rs16917496 of miR-502 and rs384262 variant in BC among a sub population of Iranian patients [20]. MiR-21 is involved in regulation of cell proliferation and apoptosis through targeting various factors such as PTEN and PDCD4 [24, 25]. Another study also showed that there was a high levels of miR-21 expression in aggressive breast tumors. Moreover, a significant under expression of miR-205 was observed in ER/PR/HER2 negative breast tumors compared with normal samples. The miR-342 under and over expressions were also observed in ER/PR negative and ER/PR positive BC tissues respectively in an Iranian population [26]. Although, MiR-34a and let-7 are as tumor suppressors are observed in normal cells, their under expression is also observed in tumors. MiR-34a is one of the targets of p53. MiR-34a also targets the BCL2 and caspase 3 [27]. It has been reported that the p53, miR34a, and let-7a were significantly down regulated in BC in comparison with normal samples, however, BCL2 was up regulated in a sub population of Iranian patients [28]. MiR-328 inhibits the BCRP/ABCG2 expression which is an ABC transporter protein involved in cellular defence and multi-drug resistance. It has been observed that the tumor tissues had higher levels of miR-328 expression in comparison with normal margins among a sub population of Iranian BC patients [29]. Significant miR-132/miR-212 downregulation and miR-22 upregulation were reported in BC samples compared with corresponding normal margins among Iranian cases. Moreover, high-grade samples had decreased expression of miR-132, miR-212, and miR-22, whereas the advanced stage (III) tumors had increased expression of these markers [30]. HOX10 transcription factor is one of the targets of miR196a2 [31]. It has been shown that the miR-196a expression in BC patients harboring C/C rs11614913 was higher than that in the cases with TT genotype. The rs11614913 polymorphism was introduced an early detection marker among a sub population of Iranian BC patients [32]. Long non-coding RNAs (lncRNA) are a class of transcripts longer than 200 nucleotides. Beside the aberration in coding RNAs, the deregulation of lncRNA is also related with tumor progression. They exert their post-transcriptional regulatory functions through interaction with DNA, RNA, and protein molecules. CCAT2 is a lncRNA that exerts its oncogenic function through regulation of WNT/β-catenin pathway [33, 34]. It has been shown that there was lower levels of CCAT2 expression in tumor tissues compared with normal margins in a group of Iranian BC patients. Moreover, significant converse correlations were also observed between CCAT2 expression, stage, and lymph node involvement in which the early stage tumors without metastatic lymph nodes had higher levels of CCAT2 expression [35]. HOX transcript antisense intergenic RNA (HOTAIR) is also a lncRNA, which binds to LSD1 and PRC2 to promote HOXD repression through histone modification and chromatin remodeling [36]. It has been shown that the HOTAIR rs920778 and rs12826786 polymorphisms were significantly correlated with high risk of
| Study (et al.) | Year | Gene | Type | Population | Results |
|---------------|------|------|------|------------|---------|
| Danesh [17]   | 2018 | miR-218-2, miR-301b | Sporadic | 288 Controls 266 Patients | Polymorphism was correlated with BC risk |
| Heydari [19]  | 2018 | mir-140-3p | Sporadic | 40 Controls 40 Patients | Over expression |
| Parchami Barjui [20] | 2017 | miR-502 | Sporadic | 231 Controls 240 Patients | Polymorphism was correlated with BC risk |
| Omrani [21]   | 2014 | hsa-miR-499 | Sporadic | 203 Controls 236 Patients | Polymorphism was correlated with BC risk |
| Hashemi [23]  | 2016 | mir-608 | Sporadic | 192 Controls 160 Patients | Polymorphism was correlated with BC risk |
| Savad [26]    | 2012 | miR-342 | Sporadic | 77 N/T | Over expression in ER/PR positive tumors |
| Mansoori [28] | 2016 | miR34a, let-7a | Sporadic | 45 N/T | Under expression |
| Saberi [29]   | 2016 | miR-328 | Sporadic | 28 N/T | Over expression |
| Damavandi [30] | 2016 | miR-132, miR-212, and miR-22 | Sporadic | 36 N/T | Correlation with grade and stage |
| Nejati-Azar [32] | 2018 | miR-196a | Sporadic | 200 Controls 200 Patients | Polymorphism was correlated with BC risk |
| Sarrafzadeh [35] | 2017 | CCAT2 | Familial/ Sporadic | 48 N/T | Correlation with stage an lymph node metastasis |
| Hassanzarei [37] | 2017 | HOTAIR | Sporadic | 231 Controls 220 Patients | Polymorphism was correlated with BC risk |
| Miri [42]     | 2012 | eRF3a/GSPT1 | Familial/ Sporadic | 250 Controls 250 Patients | Polymorphism was correlated with BC risk |
| Hosseini [45] | 2011 | MTHFR | Sporadic | 306 Controls 294 Patients | Polymorphism was correlated with BC risk |
| Rezaei [46]   | 2017 | MTHFR | Familial/ Sporadic | 84 Patients | Polymorphism was correlated with BC risk |
| Jahangiri [48] | 2018 | DNMT1, DNMT3A, and DNMT3B | Sporadic | 72 Patients | Correlation with grade |
| Eftekhari [49] | 2014 | DNMT3B | Sporadic | 138 Controls 100 Patients | Polymorphism was correlated with BC risk |
| Hashemi [51]  | 2012 | CASP8 | Sporadic | 203 Controls 236 Patients | Polymorphism was correlated with BC risk |
| Aghababazadeh [52] | 2017 | CASP8 | Familial/ Sporadic | 27 N/T | Under expression |
| Eskandari-Nasab [54] | 2015 | TP53 | Sporadic | 203 Controls 236 Patients | Polymorphism was correlated with BC risk |
| Payandeh [55] | 2016 | PS3 | Sporadic | 231 Patients | Correlation with grade and lymph node metastasis |
| Rostamizadeh [58] | 2013 | BCL-2 | Sporadic | 40 Patients | Correlation with grade and survival |
| Golmohammadi [61] | 2016 | PTEN | Sporadic | 100 Patients | Correlation with stage and survival |
| Sadeg [62]    | 2011 | PTEN | Sporadic | 20 Controls 57 Patients | Hypermethylation was correlated with stage and lymph node metastasis |
| Yari [63]     | 2016 | PTEN | Familial/ Sporadic | 50 Controls 103 Patients | Methyltion |
| Ghaffari [64] | 2016 | BIRC5 | Sporadic | 40 Patients | Correlation with age |
| Vallian [70]  | 2009 | p16INK4A | Sporadic | 70 Controls 70 Patients | Methyltion was correlated with stage |
| Salimi [72]   | 2012 | ATM and cyclinD1 | Sporadic | 119 Patients | ATM under expression and cyclinD1 over expression |
| Mehdipour [73] | 2011 | ATM | Sporadic | 248 Controls 129 Patients | Polymorphism was correlated with BC risk |
| Amininia [75] | 2014 | CCNE1 | Sporadic | 225 Controls 266 Patients | Polymorphism was correlated with BC risk |
| Hajikhan Mirzaei [78] | 2012 | DBC2 | Sporadic | 50 Patients | Methyltion |
| Golmohammadi [79] | 2017 | AURKA | Sporadic | 100 Controls 100 Patients | Polymorphism was correlated with BC risk |
Table 1 (continued)

| Study (et al.)    | Year | Gene                  | Type               | Population          | Results                                                                 |
|-------------------|------|-----------------------|--------------------|---------------------|-------------------------------------------------------------------------|
| Mojgan [80]       | 2012 | ERCC1                 | Sporadic           | 126 Controls 300 Patients | Polymorphism was correlated with BC risk                               |
| Jalali [83]       | 2016 | XRCC1                 | Sporadic           | 200 Controls 100 Patients | Polymorphism was correlated with BC risk                               |
| Rezaei [86]       | 2016 | FEN1                  | Sporadic           | 225 Controls 266 Patients | Mutation                                                               |
| Majd [88]         | 2014 | EMSY                  | Familial/Sporadic  | 116 Patients         | Correlation with tumor size and lymph node metastasis                 |
| Hallajian [91]    | 2017 | ATM, RADS1, and BRCA1 | Sporadic           | 50 Patients          | Under expression                                                       |
| Darbeheshti [94]  | 2018 | BRCA1                 | Sporadic           | 53 Patients          | Correlation with grade and lymph node metastasis                      |
| Majd [95]         | 2011 | BRCA1                 | Familial/Sporadic  | 156 Patients         | Correlation with grade                                                 |
| Rezaei [96]       | 2015 | APOBEC3               | Sporadic           | 217 Controls 262 Patients | Mutation                                                               |
| Abbasi [98]       | 2017 | FANCA                 | Familial/Sporadic  | 295 Controls 304 Patients | Mutation                                                               |
| Hashemi [102]     | 2014 | hTERT                 | Sporadic           | 225 Controls 266 Patients | Polymorphism was correlated with BC risk                               |
| Hagh [108]        | 2015 | HLA-G                 | Sporadic           | 255 Controls 227 Patients | Polymorphism was correlated with BC risk                               |
| Mahmoodi [109]    | 2012 | HLA-II                | Sporadic           | 80 Controls 100 Patients | Polymorphism was correlated with BC risk                               |
| Ghaderi [110]     | 2001 | HLADR8B1              | Sporadic           | 36 Controls 36 Patients | Polymorphism was correlated with BC risk                               |
| Faghih [113]      | 2009 | IL13                  | Sporadic           | 195 Controls 305 Patients | Polymorphism was correlated with BC risk                               |
| Khodadadi [119]   | 2014 | IL-27 and IL-23       | Sporadic           | 50 Controls 50 Patients | Over expression                                                        |
| Vahed [120]       | 2018 | CCR7                  | Sporadic           | 70 N/T               | Correlation with stage, grade, and lymph node metastasis              |
| Jafarzadeh [123]  | 2015 | CCL22                 | Sporadic           | 100 Controls 100 Patients | Correlation with stage                                                 |
| Dayer [124]       | 2018 | CXCR4                 | Sporadic           | 36 N/T               | Over expression in HER2 positive tumors                                |
| Jaberi [127]      | 2010 | FOXP3 and CTLA-4      | Sporadic           | 40 Controls 55 Patients | Correlation with stage and grade                                       |
| Hamidinia [128]   | 2013 | FOXP3 and OX40        | Sporadic           | 40 Controls 40 Patients | Correlation with stage                                                 |
| Rostami [134]     | 2015 | Leptin                | Sporadic           | 171 Controls 203 Patients | Polymorphism was correlated with BC risk                               |
| Mohammadzadeh [136]| 2015 | Leptin                | Sporadic           | 100 Controls 100 Patients | Polymorphism was correlated with BC risk                               |
| Pornour [140]     | 2014 | DRD2, DRD4            | Sporadic           | 30 Controls 30 Patients | Over expression                                                        |
| Amani [141]       | 2014 | TGFβ1                 | Sporadic           | 110 Controls 110 Patients | Polymorphism was correlated with BC risk                               |
| Parvizi [142]     | 2016 | TGF-β                 | Sporadic           | 100 Controls 100 Patients | Polymorphism was correlated with BC risk                               |
| Tabatabaeian [143]| 2013 | HER-2                 | Familial/sporadic  | 15 Controls 80 Patients | Over expression                                                        |
| Panahi [144]      | 2013 | HER-2                 | Familial           | 299 Patients         | Correlation with ER/PR                                                 |
| Amirifard [145]   | 2016 | HER-2                 | Familial/sporadic  | 130 Patients         | Correlation with stage and age                                         |
| Salimi [146]      | 2016 | ERBB4                 | Familial/sporadic  | 192 Controls 172 Patients | Polymorphism was correlated with BC risk                               |
| Mansourown Bidkani[147]| 2018 | ERBB4                 | Familial/sporadic  | 148 Controls 172 Patients | Polymorphism was correlated with BC risk                               |
Table 1 (continued)

| Study (et al.) | Year | Gene | Type       | Population       | Results                                                      |
|---------------|------|------|------------|-------------------|--------------------------------------------------------------|
| Bagheri [148] | 2016 | ERBB4| Sporadic   | 146 Controls      | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 146 Patients      |                                                              |
| Eskandari-Nasab [152] | 2012 | NGX6 | Sporadic   | 203 Controls      | Under expression                                             |
|               |      |      |            | 236 Patients      |                                                              |
| Seifi-Alan [154] | 2018 | NRP1 | Sporadic   | 48 N/T            | Correlation with stage, grade, and lymph node metastasis     |
| Javadi [156]  | 2012 | IGF-1| Familial/sporadic | 224 Controls | Mutation                                                    |
|               |      |      |            | 215 Patients      |                                                              |
| Azizi Tabesh [158] | 2017 | PIK3CA| Sporadic   | 80 Patients       | Mutation                                                    |
| Sanaei [159]  | 2017 | KRAS | Sporadic   | 204 Controls      | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 244 Patients      |                                                              |
| Nazouri [160] | 2017 | SPHK1| Sporadic   | 120 Patients      | Correlation with BMI                                         |
| Heshmatpour [164] | 2014 | PIK3CA| Sporadic   | 200 Controls      | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 200 Patients      |                                                              |
| Ghalaie [165] | 2018 | APPL2 and OCC1 | Sporadic | 30 N/T | APPL2 under expression and OCC1 over expression |
| Karami-Tehrani [166] | 2016 | RIP1 K and RIK3K| Sporadic | 20 Normal | Correlation with grade                                    |
|               |      |      |            | 45 Tumor          |                                                              |
| Nikseresht [168] | 2010 | UBE2Q2| Sporadic   | 21 N/T            | Over expression                                             |
| Hashemi [170]  | 2012 | GSTM1, GSTT1, GSTP1 | Sporadic | 152 CONTROLS 134 PATIENTS | Polymorphism was correlated with BC risk               |
| Sharif [171]   | 2017 | GSTO1, GSTO2 | Sporadic | 150 Controls | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 153 Patients      |                                                              |
| Saadatian [173] | 2014 | CYP1A1| Sporadic   | 100 Controls      | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 100 Patients      |                                                              |
| Saghaei [174]  | 2018 | CYP2D6| Familial/sporadic | 84 Patients | Polymorphism was correlated with BC risk                     |
| Yazdi [179]    | 2015 | CYP2D6| Sporadic   | 101 Patients      | Polymorphism was correlated with BC risk                     |
| Homaei-Shandiz [184] | 2016 | HSP27| Sporadic   | 65 Controls       | High levels of serum anti Hsp27                             |
|               |      |      |            | 97 Patients       |                                                              |
| Ghafouri [187] | 2016 | ABCG2 | Sporadic   | 200 Controls      | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 100 Patients      |                                                              |
| Estiar [189]   | 2017 | CEACAM19| Sporadic  | 75 Patients       | Over expression                                             |
| Moazzezy [192] | 2014 | CA15-3 and CEA | Sporadic | 30 Controls | Over expression                                             |
| Mansouri [193] | 2016 | MUC1 | Sporadic   | 50 Patients       | Over expression                                             |
| Zarei [196]    | 2017 | CDH1 | Sporadic   | 200 Controls      | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 100 Patients      |                                                              |
| Esmaeili [198] | 2018 | CD44 | Familial/sporadic | 175 Controls | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 175 Patients      |                                                              |
| Sadeghi [202]  | 2017 | EpCAM| Sporadic   | 122 Patients      | Correlation with grade                                      |
| Taghizadeh-Kermani [204] | 2014 | CD10 | Sporadic   | 150 Patients      | Correlation with grade, lymph node metastasis, and tumor size |
| Fard [207]     | 2018 | CAV-1| Sporadic   | 203 Controls      | Polymorphism was correlated with BC risk                     |
|               |      |      |            | 203 Patients      |                                                              |
| Mobasher [208] | 2016 | SYCP3 | Sporadic   | 47 Patients       | Over expression                                             |
| Malek-Hosseini [209] | 2017 | SDC1 | Familial/sporadic | 30 Controls | Correlation with tumor size                                |
|               |      |      |            | 61 Patients       |                                                              |
| Karami-Tehrani [213] | 2012 | PDE5 and PDE9 | Sporadic | 70 N/T | Correlation with stage, grade, and lymph node metastasis     |
| Karami-Tehrani [215] | 2012 | PKG  | Sporadic   | 70 N/T            | Under expression                                             |
| Paryan [218]   | 2016 | NOTCH1| Sporadic   | 20 N/T            | Correlation with tumor type                                 |
| Taghavi [220]  | 2016 | WISP1| Familial/sporadic | 15 Controls | Correlation with age and tumor size                         |
|               |      |      |            | 85 Patients       |                                                              |
BC, and rs1899663 variant also showed a significant correlation with low risk of BC among a sub population of Iranian cases [37]. Therefore, HOTAIR have probably an important role in BC progression via polycomb complexes and can be introduced as efficient prognostic and diagnostic marker for the BC. Deregulation of translation machinery and ribosome biogenesis are common features of tumor cells in post transcriptional level and epigenetic. eRF1 and eRF3 are the main terminators in eukaryotic translation process, in which the RF3 functions as an enhancer of RF1 through GTPase activity [38]. Moreover, RF3 is involved in poly (A) tail stabilization via interaction with PABP [39]. RF3 has two isoforms including RF3a and RF3b that are encoded by eRF3a/GSPT1 and eRF3b/GSPT2 genes, respectively [40, 41]. The association between the GGC repeat polymorphism in exon 1 of eRF3a/GSPT1 and the potential genetic susceptibility for BC progression was evaluated among a sub population of Iranian subjects. It has been shown that the Iranian patients harboring the 12-GGC and 7-GGC alleles of eRF3a/GSPT1 have a high risk of BC. Moreover, the homozygote 7-GGC repeat can be correlated with the age of BC progression among a sub population of Iranian females [42]. The tumor progression is related with genetic and epigenetic changes. DNA methylation is one of the most important epigenetic mechanism during the neoplastic transformation. Role of DNA methylation in tumorigenesis is mainly related to the promoter hypomethylation and hypermethylation of oncogenes and tumor suppressor genes respectively. Methylene tetrahydrofolate reductase (MTHFR) regulates folate metabolism, DNA methylation, synthesis, and repair [43, 44].

There is probably a correlation between MTHFR 1298AA and 677CC genotype and higher risk of BC. Moreover,

| Study (et al.) | Year | Gene | Type | Population | Results |
|---------------|------|------|------|------------|---------|
| Madjd [224]   | 2012 | ALDH1| Familial/Sporadic | 127 Patients | Correlation with BRCA1 |
| Jahangiri [229]| 2018 | PAX2 | Sporadic | 72 Patients | Correlation with survival |
| Estiar [233]  | 2017 | NDRG3| Sporadic | 6 Normal 88 Tumor | Correlation with survival |
| Hosseini [234]| 2014 | ERα | Sporadic | 10 Normal 19 Tumor | Over expression |
| Abbasi [235]  | 2013 | ERα | Familial/Sporadic | 147 Controls 150 Patients | mutation |
| Farzaneh [236]| 2016 | CYP19| Sporadic | 135 Controls 134 Patients | Polymorphism was correlated with BC risk |
| Kamali-Sarvestani [241]| 2005 | TNF-α | Sporadic | 160 Patients | Polymorphism was correlated with BC risk |
| Vakil Monfared [245]| 2018 | TNFSF4| Sporadic | 126 Controls 123 Patients | Polymorphism was correlated with BC risk |
| Colagar [250] | 2015 | VDR | Sporadic | 127 Controls 134 Patients | Microsatellite |
| Zhalehjoo [255]| 2017 | CYP24A1 and CYP27B1| Sporadic | 30 N/T | Correlation with stage and age |
| Shahabi [256] | 2018 | VDR | Familial/Sporadic | 214 Controls 203 Patients | Polymorphism was correlated with BC risk |
| Shahbazi [257]| 2013 | VDR | Sporadic | 156 Controls 140 Patients | Polymorphism was correlated with BC risk |
| Ebrahimi [260]| 2017 | CYP17| Familial/Sporadic | 205 Patients | Polymorphism was correlated with BC risk |
| Esmaeili [263]| 2015 | AKAP3| Sporadic | 162 N/T | Correlation with stage and tumor size |
| Noushrasofdein [266]| 2015 | WBP2NL| Sporadic | 30 Normal 50 Tumor | Over expression |
| Rastgosalamo [267]| 2016 | MAGE-1| Sporadic | 113 Patients | Correlation with lymph node metastasis and tumor size |
| Dianatpour [268]| 2012 | TSGA10| Sporadic | 50 Patients | Expression |
| Kazemi-Oula [272]| 2015 | ODF4 and RHOXF2| Familial/Sporadic | 40 N/T | Over expression |
| Arezi [278]| 2018 | ND4 | Sporadic | 28 Normal 60 Tumor | Mutation |
| Ghaffarpour [282]| 2014 | ATPase6| Sporadic | 49 Patients | Mutation |

* a Tumor tissues and normal margins
* b Both of familial and sporadic patients among cases
the frequency of MTHFR 677 CT, TT and 1298 CT, AA variants in BC patients were lower than that in the healthy controls in an Iranian population [45]. It has been also observed that the C677T TT variant of MTHFR was significantly correlated with elevated risk of familial BC in Iranian patients [46]. Tamoxifen has been used as a treatment option for hormone responsive breast tumors. However, about onethird of patients are resistant and face with relapse [47]. The expression of DNMT1, DNMT3A, and DNMT3B DNA methyltransferases in tamoxifen resistant patients were higher than that in the tamoxifen sensitive Iranian BC patients. There were significant associations between their protein expression and tumor grade, and also DNMT3B expression and lymph node metastasis in tamoxifen sensitive group. There was significant correlation between DNMT3A and DNMT3B expression and high histologic grade in tamoxifen resistant group. Generally they showed that the DNMTs overexpression has a negative association with survival in Iranian tamoxifen-treated BC cases [48]. Another group showed that, the DNMT3B 149 C→T polymorphism was significantly associated with reduced BC risk among patients in Southern Iran [49].

Aptoptosis, DNA repair, and cell cycle

Aptoptosis is a critical process through the organ development and is a defense mechanism against deregulated cell proliferation and tumorigenesis. It includes several pathways such as extrinsic and intrinsic. Death receptors are the activators of extrinsic pathway which subsequently activates the caspase-8. Then, the caspase-8 initiates a cascade by cleaving caspase-3, caspase-7, or Bid [50]. A group evaluated the probable association between CASP8 6N del variant and BC susceptibility in Iranian patients. They showed that there was a significant higher frequency of del allele in the control group compared with BC cases, which highlights the anti tumor role of the CASP8 −652 6N del variant among Iranian
Another group also assessed the levels of CASP8 expression in tumor in comparison with normal margins of Iranian BC patients, which showed decreased CASP8 expression in tumor tissue. Moreover, there was a significant correlation between CASP8 expression and HR status [52]. TP53 as a tumor suppressor regulates the cell cycle and apoptosis [53]. It was shown that the TP53 16-bp INS/DEL polymorphism can be associated with risk of BC among a sub population of Iranian patients [54]. There was also significant correlations between p53 expression, lymph node involvement, age, and tumor grade in Kurdish BC patients in Western Iran [55]. The mitochondrial pathway of apoptosis process is associated with BCL-2 which is also a prognostic factor in BC for its relation with defence mechanisms against the genotoxic damages [56, 57]. It has been observed that there was higher levels of BCL-2 mRNA expression in tumors compared with normal margins in a sub population of Iranian BC subjects. BCL-2 over expression was positively associated with tumor grade and ER/PR, and negatively with tumor size. There was also a significant correlation between high levels of BCL-2 mRNA expression and survival rates [58]. PTEN is a tumor suppressor via the stimulation of apoptosis in tumor cells and suppression of cell proliferation. Moreover, It is a negative regulator of intracellular PIP3 and AKT/PKB signaling pathway. PTEN regulates the p53 stability through AKT-MDM2 pathway or direct interaction [59]. Moreover, PTEN-p300 complex maintains P53 acetylation following the DNA damage [60]. A significant correlation between PTEN expression and stage has been reported among a group of Iranian BC patients, in which advanced stage tumors had lower levels of PTEN expression. Moreover, the tumors without PTEN expression had lower survival rates compared with tumors with PTEN expression, which can be introduced as a prognostic marker [61]. It has been observed that the majority of BC patients had PTEN promoter methylation which was not observed among the normal cases. Moreover, there was a correlation between PTEN hypermethylation and lymph node metastasis and advanced stages tumors among a sub population of Iranian patients [62]. Another study have reported there was association between PTEN promoter methylation and BC susceptibility among a sub population of Iranian patients [63]. BIRC5 is an anti apoptotic factor and cell cycle regulator which is only expressed at the embryonic stage. It has been reported that the BIRC5 is associated with early onset BC progression, in which there was a significant correlation between BIRC5 up regulation and Iranian patients who were younger than 40 years [64].

DNA repair and cell cycle regulation are important processes related to the cancer susceptibility and chemotherapeutic responses. Cell proliferation is regulated by signaling pathways to limit the proliferation in adequate ratio. The cell cycle is regulated by several factors such as cyclins, CDK, and CDKIs. G1 to S progression is related with cyclin D and CDK 4/6, which is repressed by INK4 family [65]. PI16INK4A is belonged to the INK4 family [66], and its deregulation has been reported in different tumors [67]. The p16INK4A is responsible for the G0 and G1 cell cycle arrest through suppression of cyclin D–CDK4/6, and it also has a critical role as an inhibitor of pRb phosphorylation [68, 69]. It has been reported that there was a correlation between p16INK4A promoter methylation and primary BC, in which the hypermethylated cases were in primary tumors with stages of I, II and III. Therefore, they concluded that the p16INK4A promoter methylation can be introduced as an efficient marker of early detection among a sub population of Iranian sporadic BC patients [70]. Cyclin D1 is one of the main cell cycle regulators that binds with CDK4/6 to phosphorylate pRb through the cell cycle. The ataxia telangiectasia-mutated (ATM) is also involved in DNA damage recognition [71]. A study has evaluated the ATM and cyclin D1 expression in a sub population of Iranian BC patients. They showed about 21.6% of cyclin D1 under-expression which were mostly in HER-2–positive tumors. In the case of ATM, about 50% had ATM under-expression. The levels of ATM expression in normal margins were lower than normal controls which can be related to the epigenetic regulation of ATM expression. Therefore, they concluded that the ATM and cyclin D1 under and over expressions respectively can be associated with tumor progression among the Iranian BC patients [72]. It has been observed that there was a significant difference of D1853N ATM polymorphism between patients and healthy controls, introducing this polymorphism as a diagnostic marker among a sub population of Iranian cases [73]. Cyclins and CDKs activate the E2F transcription factor through inhibition of retinoblastoma protein. Cyclin E/CDK2 complex is associated with DNA replication and chromosomal stability [74]. A correlation between CCNE1 rs1406 C/A polymorphism and elevated risk of BC has been shown among an Iranian population in southeast of Iran [75]. DBC2 inhibits cell proliferation via CCND1 down-regulation [76], and is associated with ubiquitination, cell cycle, and apoptosis [77]. Methylation status of DBC2 promoter sequence was assessed in blood and BC tissue samples of an Iranian sub population, showed a correlation between aberrant DBC2 methylation and tumor progression in sporadic cases [78]. The AURKA is involved in cell cycle regulation, G2/M transition, centrosome division, and genomic instability. It has been observed that the BC cases had higher frequency of Ile/Ile variant at F31I locus of AURKA in
endonuclease 1 (FEN1) tumor suppressor is a critical factor among Iranian Kurdish BC patients [83]. Flap stage. They introduced the Trp194 allele of XRCC1 as a cases. Moreover, this variant was also correlated with more frequent among patients compared with normal reported that the Arg194Trp XRCC1 polymorphism was compared with familial cases. There was a direct correlation between FEN1 haplotypes and BC susceptibility among a sub population of Iranian patients in Southeastern Iran [86]. BRCA family mediates double stranded DNA break repairs and chromatin remodeling [87]. EMSY is an inhibitor of the BRCA2 transactivity. It has been shown that the majority of a group of Iranian BC patients had EMSY protein expression. The sporadic cases had higher levels of EMSY expression compared with familial cases. There was a direct correlation between EMSY expression, larger tumor size, higher relapse, and increased lymph node involvement [88]. Homologues Recombination (HR) is one of the main processes during the DSB repair. RAD51 is a key factor in HR regulation. DSB activates the ATM that subsequently phosphorylate and activate the BRCA1 which is associated with RAD51 [89, 90]. It has been shown that there were significant ATM, RAD51, and BRCA1 down regulations in BC tissues compared with normal margins in a sub population of Iranian subjects. ATM under expression was significantly correlated with tumor stage, vascular invasion, and malignant behavior. Down regulation of RAD51 was also significantly correlated with lymph nodes metastasis, age, and grade of tumor [91]. BRCA1 is a nuclear phosphoprotein involving in DSB repair, cell cycle regulation, and apoptosis [92, 93]. There was significant correlations between BRCA1 downregulation, high grade, and lymph node metastasis. Low levels of BRCA1 expression were observed in majority of triple-negative and luminal tumors in comparison with normal tissues among a sub population of Iranian cases [94]. The altered BRCA1 expression is more frequent in primary BC, and loss or decreased BRCA1 expression in high-grade were more frequent in comparison with differentiated tumors. Moreover, there was a significant inverse association between the levels of BRCA1 and CD44 expressions in Iranian BC patients [95]. APOBEC3 is a cytidine deaminase involved in RNA editing, cell cycle regulation, and repression of the retrovirus replication. It has been observed that the APOBEC3 deletion had a significant correlation with increased risk of BC among a sub population of Iranian cases [96]. The FANCA is a tumor suppressor related to DNA repair [97]. Duplication in FANCA promoter sequence can be associated with increased risk of BC among Iranian cases [98]. Telomeres are repeated sequences at the end of linear chromosomes to maintain them against the loss of genetic information through the cell proliferation [99]. Telomere shortening leads the cells up to the senescence and apoptosis, which is an intra cellular defence mechanism against genomic instability and tumorigenesis [100]. hTERT is the main subunit of telomerase complex to maintain the telomere stability [101]. The hTERT rs2736098 variant increased the risk of BC in a subpopulation of Iranian patients in southeast Iran [102].

Immune response

The immune system is able to find tumor cells through tumor-specific antigens or other induced factors by cellular stress [103]. However the microenvironment changes by tumor cells can be resulted to tumor escape from immune response [104]. HLA system has important role in tumor antigen presentation for the immune system [105, 106]. HLA-G has immunosuppressive functions during the tumor progression [107]. A mutational analysis on a sub population of BC patients in northwestern Iran showed a slightly higher allele frequency of HLA-G 14 bp deletion among patients. It seems that the high HLA-G expression induces tumor cells toward progressive stages. They concluded that the HLA-G 14 bp InDel polymorphism is probably a risk factor of BC progression among this population [108]. HLA-I and 2 present the antigens to the CD8+ T and CD4+ T cells, respectively. HLA-DRB1/DQB1 and HLA-DQA1 are belonged to the HLA-2 beta and alpha chains paralogues, respectively. It has been shown that the HLA-DQA1*0301 variant is correlated with elevated risk of early onset BC progression. Whereas, the HLA-DQA1*0505 and HLA-DQB1*0602 variants were associated with decreased risk of BC among young patients. They concluded that the HLA-II polymorphisms are risk factors of BC among a sub population of Iranian patients [109]. It has been observed that there was a significant association betweenHLA-DRB1*12 allele and risk of BC among a sub population of Iranian patients [110]. Interleukin-13 is mainly secreted by activated TH2 lymphocytes and Natural Killer T cells [111, 112]. It has been shown that there was a correlation
between CCA and ACA haplotypes of IL13 gene and risk of BC. Moreover, −1512C and −1055C alleles are involved in BC progression among a sub population of Iranian patients [113]. IL-27 is a heterodimeric cytokine comprising of EBI3 and P28 subunits that induces the CD4+ T cell proliferation through activation of STAT1 and 3 transcription factors [114, 115]. Moreover, IL-27 in association with TGF-β has a critical function in generation of IL-10-producing Tr1 cells [116]. IL-23 also regulates the memory CD4+ T cells proliferation through STAT3 activation [117, 118]. It has been reported that there was significantly higher levels of IL-27 and IL-23 expressions in BC peripheral bloods compared with normal cases, which can be introduced for the immunotherapy in Iranian BC patients [119]. CCR7 chemokine receptor is a G-protein coupled receptor involved in migration of immune cells to the lymphoid organs. It has been observed that the CCR7 expression was significantly associated with lymph node involvement, garde, and stage. Therefore, they introduced CCR7 as a prognostic marker among a sub population of Iranian BC patients [120]. CCL22 chemokine is produced by macrophages and DCs following the activation with microbial infection or CD40. The CCL22 production is regulated by Th1/2 cytokines such as IL-4, IL-5, and IFN-γ [121]. Therefore, CCL22 is associated with Th2- and Treg cells through inhibition of the immune responses against microbial infections and cancer cells [122]. It has been shown that the BC patients had significantly higher serum levels of CCL22 compared with healthy cases. There was also a direct correlation between the levels of CCL22 expression and stage of tumor. The frequencies of CC and C genotypes at rs223818 of CCL22 were significantly higher in BC patients in comparison with normal cases. Carriers of such genotypes also had higher serum levels of CCL22 compared with cases harboring GG or G variants, which highlighted the role of SNP rs223818 in BC risk via upregulation of the CCL22 [123]. CXCL12 is a chemokine that binds to its receptor (CXCR4) to activate MAPK1/MAPK3 through intracellular calcium ion which is involved in migration and adhesion. It has been shown that there was a correlation between HER2 and CXCR4 expression in a group of Iranian BC patients in which the HER2 positive tumors significantly had higher levels of CXCR4 expression in comparison with the HER2 negative tumors. They suggested the HER2 as a probable inducer of CXCR4 among BC patients [124]. T-regulatory cells express cytotoxic T-lymphocyte antigen-4 (CTLA-4) and FoxP3 transcription factor [125, 126]. It has been shown that there was higher levels of FOXP3 and CTLA-4 mRNA expressions in blood samples of early stage and low grade BC patients compared with healthy subjects in an Iranian population. They highlighted the importance of regulatory T cells inhibitory mechanisms through the tumor progression which prepares opportunity for the tumor cells to hide from immune system [127]. A significant correlation has been also reported between FOXP3 and OX40 expressions and tumor stage in peripheral blood samples of Iranian BC patients [128]. Obesity is one of the main socio-epidemiological health problems globally and a negative BC prognostic factor [129]. The high ratio of adipose tissue increases the risk of tumor relapse in BC [130]. Negative effect of obesity on BC survival is associated with inflammatory cytokines such as leptin and IL-6 which are secreted by adipose tissue [131]. Leptin is an adipocytokine which is important in tumor progression through the activation of AKT signaling pathway [132]. Leptin is involved in cell proliferation, migration, and survival via regulation of various factors such as AP1, ERK2, and MAPK [133]. It has been reported that the leptin G-2548A (rs7799039) polymorphism was significantly correlated with risk of BC among a sub population of Iranian patients. They concluded that the females harboring AA genotype have an earlier menarche age and higher risk of breast cancer [134]. It has been also shown that the obese BC had higher serum leptin concentration compared with non-obese Iranian BC cases. Therefore, the inflammation has a key function in distant metastasis, since the adipose is the main source of leptin the weight loss through the physical activity can be an efficient option to decrease the negative role of leptin in BC progression [135]. LEP-2548G/A frequency was evaluated and showed the Iranian patients harboring LEP-2548G variant had a noticeable increased risk of BC [136]. Chronic stress is involved in tumorigenesis through secretion of neurotransmitters like during lymphocyte migration and angiogenesis. Dopamine is a neurotransmitter which has proliferative effects and induces the T cells for secretion of anti immune cytokines [137]. Dopamine receptors are from G-protein family which play important roles to induce or suppress intracellular cAMP [138]. The stress can alter dopamine receptor expression. Dopamine receptors (DRD1-DRD5) are categorised into D1 (stimulatory receptors) and D2 (inhibitory receptors) families [138, 139]. It has been reported that there was significantly higher levels of DRD2-DRD4 in a group of Iranian BC cases compared with healthy controls [140]. The transforming growth factor (TGF)-β is a pleiotropic cytokine expressed in several cells including peripheral blood mononuclear cells and platelets that plays critical roles in regulation of cell proliferation, apoptosis, and angiogenesis. The TGF-beta superfamily are involved in cell proliferation through activation of SMAD transcription factors. It has an anti cancer function in normal cells, whereas it promotes the tumor progression in advanced stage tumors. It has been observed
that there was a significant difference in frequency of TGFβ1 “GTGCCCAGC” haplotype between BC and healthy controls among an Iranian population [141]. Moreover, it has been shown that there was significant correlations between TT and AA genotype of −509T/T and −800G/A TGF-β respectively and BC risk among a sub population of Iranian patients [142].

Kinases and growth factors
The human epidermal growth factor 2 (HER-2) is a transmembrane tyrosine kinase receptor which is involved in cell proliferation. It was shown that fourteen out of 60 (23%) had HER-2 overexpression in a subpopulation of malignant BC patients in central Iran [143]. There was also an inverse correlation between HER-2 expression and ER/PR levels in a group of Iranian BC cases [144]. Another study on BC patients in Kermanshah province of Iran have shown a significant association between age, stage, and HER2-neu expression. Therefore, they introduced the HER2-neu as an efficient prognostic and diagnostic marker in that population [145]. ErbB4 is a tyrosine kinase receptor belonging to the EGFR subfamily. Frequency of rs11895168 was analyzed in a subpopulation of central Iranian BC patients, and observed that none of the normal cases harbored the rs11895168 C allele. They introduced a significant correlation between C allele and higher risk of breast cancer, which can be related to the miR-1276 binding changes [146]. Another study has shown that there was a significant correlation between rs13423759 allele C of ERBB4 and increased risk of BC which can be associated with role of this allele in strengthening the miR-548as-3p/ErbB4 interaction. The rs13423759 allele A is also significantly associated with decreased risk of breast cancer. Therefore, they highlighted the role of rs13423759 as an efficient diagnostic biomarker among a group of Iranian BC patients [147]. The rs1836724 polymorphism of ErbB4 was correlated with risk of BC, in which the T allele carriers had decreased expression of ErbB4 and higher susceptibility for BC among a group of Iranian patients [148]. NGX6 has an epidermal growth factor (EGF)-like domain which functions as a negative growth factor through apoptosis induction and cell proliferation arrest [149, 150]. NGX6 exerts its negative role on cell cycle via down regulation of cyclin D1, A, and E [151]. It has been shown that the levels of NGX6 mRNA expression in Iranian BC tumors were significantly lower than that in the normal samples [152]. Neuropilin-1 (NRP1) as a receptor for VEGF and PlGF in endothelial cells plays key roles in cell survival, angiogenesis, and EMT [153]. It has been shown that there was significant correlation between NRP1 expression and lymph node involvement in which the patients with metastatic lymph nodes had higher levels of NRP1 expression in comparison with the lymph node-negative cases. Moreover, the tumors with higher stages and grades had higher levels of NRP1 expressions. Therefore, they introduced NRP1 as a metastatic diagnostic marker among a sub population of Iranian BC patients [154]. Insulin-like growth factor 1 (IGF-1) is one of the activators of the AKT pathway, which is a cell proliferation inducer and cell death suppressor. There is a polymorphic cytosine—adenine (CA) repeat located in 1 kb upstream of the IGF-1 start site which is associated with cancer [155]. Length of this dinucleotide repeat was assessed in a group of Iranian BC patients. They showed that the patients harboring an allele longer than 19 and shorter than 20 have higher and lower risks of breast cancer, respectively. Therefore, there was a correlation between BC and length of the IGF-1 CA repeat which seems related to the ethnicity [156]. Phosphatidylinositol-3-kinase (PI3K) is a heterodimeric protein comprising of regulatory and catalytic subunits encoded by PIK3R1 and PIK3CA respectively, which is involved in apoptosis and cell proliferation [157]. Mutational analysis of PIK3CA catalytic subunit was done in a group of Iranian BC patients, and showed 45% of 80 cases had mutated PIK3CA that was higher than the recent reports. Majority of mutations were observed in three hotspots belonging to exon 9 and 20. There was a significant correlation between PIK3CA mutation and low grade tumors [158]. KRAS oncogene is a member of the small GTPase superfamily, which is also associated with PI3-kinase signaling pathway. It has been reported that the rs61764370 and rs712 polymorphisms in KRAS increased and decreases the BC risk in a sub population of Iranian patients [159]. SPHK1 catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P), which is a ligand of G protein-coupled receptors and regulates cell proliferation. SPHK1 exerts its inflammatory and anti apoptotic roles through several signaling pathways such as TNF-alpha and NF-kappa-B. It has been observed that there was a positive correlation between SPHK1 expression in ER/PR negative tumors compared with positive BC cases. Moreover, there was an association between BMI and SPHK1 expression among the Iranian ER negative BC patients [160]. The Class I PI3K family phosphorylates PIP2 to PIP3 which subsequently activates AKT as a regulator of cell proliferation, adhesion, and migration [161]. PIK3CA is the catalytic subunit of class I PI3Ks [162] that is deregulated in various cancers [163]. A highly polymorphic intronic GT dinucleotide repeat in PIK3CA had direct correlation with risk of BC in a group of Iranian patients, in which the harbors of short allele (17 repeats) and long allele (more than 16 repeats) had significantly higher and lower risk of BC progression, respectively [164]. OCC1 is involved in differentiation of adipocytes.
APPL2 is one of the small GTPase RAB5A/Rab5 effectors, which are associated with endosomal membranes and can interact with the NuRD/MeCP1 complex which is required for cell proliferation. Levels of OCC1 and APPL2 expression were assessed in BC tissues, and showed significant under and over expressions of APPL2 and OCC1 in tumors compared with corresponding normal margins, respectively. Therefore, they suggested that the OCC-1D variant suppresses the APPL2 and probably regulate the cell cycle through PI3K/AKT signaling pathway [165]. RIP1K and RIP3K are belonged to RIPK family and involved in inflammation and cell death, in response to tissue damage. It has been observed that the benign and malignant tumors had increased levels of RIP1K compared with normal tissues. Whereas the malignant tumors had decreased levels of RIP3K expression compared with normal and benign samples. Moreover the RIP1K and RIP3K had decreased and increased expressions among old Iranian BC patients with malignant tumors, respectively. The tumors with higher grade and larger size had increased levels of RIP1K expression. Whereas the RIP3K had decreased expression in malignant tumors with grade III [166].

Intracellular defense systems and drug resistance
Ubiquitin proteasome machinery is one of the main intracellular defense systems which is involved in degradation of aberrant and defective proteins. Moreover, it regulates the stability of cell cycle regulators. Ubiquitin–proteasome pathway involves several members such as Ubiquitin-activating (E1) and conjugating (E2) enzymes (E1) and ubiquitin ligases (E3). Since the lifetime regulation of cellular regulatory proteins including cell cycle and transcription factors is governed by the ubiquitin process, ubiquitine proteasome deregulation can be resulted in tumor progression [167]. UBE2Q2 expression was assessed in Iranian BC cases, and showed that the majority of tumor tissues had UBE2Q2 over expression compared with their corresponding normal margins. They introduced UBE2Q2 as a novel diagnostic marker among the Iranian BC patients [168]. Glutathione S-transferases (GSTs) as the cytoprotective factors detoxify the carcinogens and chemotherapeutic drugs through the glutathione binding. Therefore, the human polymorphisms affects the individual ability to respond toward drugs and stresses. Although, the GSTM1 is expressed in a wide spectrum of tissues such as liver, stomach, and breast, GSTT1 enzyme is mainly observed in liver and erythrocytes [169]. The association between GSTM1, GSTT1 and GSTP1 genotypes and BC were assessed in a subpopulation of Iranian cases. It was reported that the GSTM1 null and GSTP1 Ile105Val genotypes were significantly correlated with the increased risk of BC. It seems that the cases with GSTM1 null, GSTT1 null, or GSTP1 Ile105Val Genotypes have low GST detoxification capacity, which can be resulted in higher accumulation of toxic compounds in such cases [170]. GSTO1 A140D and GSTO2 N142D polymorphisms were also associated with high risk of BC in a sub population of Iranian patients [171]. Cytochrome 450 (CYP450) is involved in oxidative catalysis of anticancer drugs and hormone synthesis. Therefore, assessment of CYP450 polymorphisms is required in anticancer therapy outcomes. CYP1A1 is involved in metabolism of xenobiotics and reactive epoxide production from aromatic compounds and steroid hormones [172]. It has been reported that the heterozygote carriers of 2455G (462Val) of CYP1A1 had significantly higher risk of BC in comparison with other genotypes. Moreover, heterozygote variant was more frequent in pre-menopausal patients, highlighting the role of this variation in early onset of BC among a group of Iranian patients in Eastern Azerbaijan [173]. Non functional CYP2D6*4 and 10 alleles were also frequent among BC patients in Northern Iran [174]. Tamoxifen is treatment option of ER-positive BC in premenopausal women [175, 176]. However, some patients do not response to the tamoxifen and die from tumor recurrence [177]. Tamoxifen is metabolized by cytochrome P450 2D6 (CYP2D6) in endoplasmic reticulum [178]. It has been shown that the HER2-neu positive Tamoxifen treated patients with CYP2D6 polymorphism had lower risk of tumor relapse in a sub population of Iranian BC patients [179]. Heat shock proteins (HSPs) are induced in response to anticancer drugs to maintain the cells in lethal conditions. Their cytoprotective function involve the correction of misfolded proteins and anti-apoptotic functions. Hsp27 regulates ability of cells to respond to the heat shock and oxidative stresses [180, 181]. Moreover, Hsp27 has an anti-apoptotic function through suppression of caspase-dependent apoptosis [182, 183]. It has been observed that there was a significant higher levels of serum anti-Hsp27 antibodies in BC compared with healthy Iranian cases [184]. The ATP-binding cassette (ABC) family regulates the drugs passage across cell membranes, which alters the kinetics of drugs. The ABCG2 is related with drug resistance in tumor cells and xenobiotic detoxification [185, 186]. It has been shown that there was a significant association between A allele of ABCG2 C421A variant and response to the Anthracyclines and Paclitaxol, and also increased BC risk in a group of Iranian BC patients [187].

Cell adhesion, cytoskeletal factors, and ECM
Alterations in adhesion properties facilitate the tumor cell detachment from the primary tumor bulk and formation of secondary tumors in distant organs. The
CEACAM subfamily are belonged to the CEA family which are involved in cell adhesion, differentiation, apoptosis, and angiogenesis [188]. Levels of CEACAM19 expression was evaluated among a group of Iranian BC patients, showing a higher levels of CEACAM19 mRNA expression in tumors compared with normal tissues [189]. The MUC1 is a mucin glycoproteins expressing on the apical surface of epithelial breast cells and is involved in cell adhesion [190]. CA15-3 serum assay determines the MUC1 protein. CEA is one of the members of immunoglobulin family and is associated with tumors [191]. Serum levels of CEA and CA15-3 were assessed in BC compared with healthy controls among Iranian cases and showed a significant increase of CA15-3 and CEA in BC in comparison with normal cases. There were significant correlations between CEA and grade of tumor, and also between CA15-3 and tumor size [192]. MUC1 overexpression was also correlated with BC progression and metastasis among Iranian cases [193]. CDH1 tumor suppressor is a cell–cell adhesion glycoprotein which is associated with cell differentiation and polarity [194, 195]. A significant correlation between CDH1 −160C/A polymorphism and BC susceptibility was reported among a group of Iranian Kurdish patients in which the A allele of CDH1 −160C/A variant was significantly associated with BC metastasis [196]. CD44 is involved normally in cell adhesion, migration, angiogenesis, and apoptosis [197]. The CD44 protein increases cell proliferation and migration in BC through an interaction with hyaluronan. It has been reported that there was a significant correlation between A > G intronic polymorphism and grade 3 of tumors in Iranian BC patients, which can be related to generation of a new SC35 binding site and modulation of splicing process. Low grade (1/2) tumors were also associated with AA genotypes [198]. Epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein associated with cell–cell adhesions and is involved in cell proliferation in different cancers [199]. EpCAM induces the Lef1 transcription factor through presenilin-2 to bind with promoter sequences of target genes such as c-myc and cyclin A/E genes [200]. C-myc protooncogene has important functions in various cellular processes such as cell cycle, angiogenesis, and apoptosis [201]. It has been observed that there was a significant correlation between EpCAM/c-myc over expression and grade III among a group of Iranian BC patients [202]. Matrix metalloproteinases are involved in ECM degradation to facilitate the cell migration and metastasis during the tumor progression. CD10 is a zinc-depandent metalloproteinase that is highly expressed in kidney and lung tissues and participates in ECM degradation [203]. Regulation of cell adhesion facilitates the tumor metastasis. Therefore, tumor cells regulate the cell adhesion through proteolytic enzymes or stimulation of fibroblasts to secrete such enzymes. It has been observed that there were inverse significant associations between stromal CD10 expression, larger tumor size, metastatic lymph nodes, and grade among Iranian BC patients [204]. Caveola are structural proteins in formation of caveola which are mainly expressed in endothelial, adipose, and smooth muscle cells [205]. CAV-1 is associated with tyrosine phosphorylation and observed in a wide spectrum of cells [206]. Role of several SNPs in CAV-1 was evaluated in BC progression among a group of Iranian patients, and showed that the cases harboring homozygous AA genotype in T29107A, G21985A, and G14713A polymorphisms have higher risk of BC progression compared with the normal cases. In contrast, the C521A homozygous variant had a protective role, and it had a significant correlation with BMI. Therefore, they introduced C521A, G14713A, G21985A, and T29107A as efficient diagnostic markers of BC progression among Iranian cases [207]. The SYCP3 is a structural component of the synaptonemal complex associated with recombination and meiotic chromosome segregation. There was a noticeable SYCP3 over expression in tumors compared with normal tissues. They introduced the SYCP3 as a CTA in BC which can be used as an early detection marker among Iranian BC patients [208]. Syndecan-1(SCD1) is an ECM receptor belonging to the heparan sulfate proteoglycan family. The extracellular domain binds to the heparan and chondroitin sulfate whereas the cytoplasmic domain is associated with cytoskeleton during the cell migration. It has been reported that there was elevated serum levels of SDC1 in BC in comparison with the healthy cases, which was also positively associated with size of BC tumors among Iranian patients [209].

Cell signaling and self renewal
AMP-activated protein kinase (AMPK) is a cellular energy sensor, which is activated with elevated AMP/ATP ratio to induces the ATP generation. AMPK also acts as a tumor suppressor through cell cycle regulation. AMPK activates p53, which induces G1/S cell cycle arrest in response to the lack of glucose. Moreover, AMPK blocks CDKs via phosphorylation of p27 [210]. Levels of cAMP and cGMP as the second messengers are regulated via cyclic nucleotide phosphodiesterases (PDEs) [211]. PDE5 and PDE9 regulate the cGMP, which activates various downstream targets such as PKGs and ion channels [212]. Significant PDE5 and PDE9 over expressions has been observed in malignant tumors compared with benign tumors and normal margins. Moreover, there were significant correlations between phosphodiesterase expression and stage, grade and lymph node metastasis. Furthermore, there was a converse correlation
between levels of expressions and age of patients. They concluded that the Iranian BC patients with higher levels of phosphodiesterases may have higher risks of malignant tumors [213]. Cyclic guanosine monophosphate (cGMP) participates in various signaling pathways through Protein Kinase G (PKG). PKG I and PKG II are serine/threonine kinases mediating the effects of cGMP [214]. It has been reported that the BC tissues had lower levels of PKG expression in comparison with the normal samples, highlighting the PKG as a tumor suppressor in a group of Iranian cases [215]. Notch is one of the main signaling pathways involved in cell proliferation, migration, and self renewal [216]. This pathway is a cell to cell contact process which is activated via the ligand binding with a family of trans membrane receptors (NOTCH1-4). Ligand binding releases the intracellular domain of Notch (ICN) into the cytoplasm which eventually enters to the nucleus where it regulated the expression of NOTCH target genes [217]. Levels of NOTCH1 mRNA expression as one of the NOTCH receptors was assessed in BC patients and showed a significant increase in invasive ductal types compared with other histopathological types. They introduced the NOTCH1 as a prognostic marker of IDC among Iranian patients [218]. WNT pathway is also another important process to maintain a normal balance between cell differentiation and proliferation. It is initiated through the cell surface receptors resulting in activation of cytoplasmic b-catenin which activates the LEF/TCF/PYGO2 transcriptional complex [219]. The WISP1 is belonged to the CTGF family and involved in WNT pathway. It also functions as an anti apoptotic factor through up regulation of BCL-X and inhibition of the P53 mediated apoptosis following the DNA damage via AKT activation. It has been reported that the metastatic BC tissues had significantly reduced levels of WISP1 mRNA expression in comparison with the normal subjects. Moreover, WISP1 expression was correlated with age and tumor size [220].

Cancer stem cells (CSC) are a small subpopulation of cells with self renewal and chemoradiotherapeutic resistance abilities [221]. Aldehyde dehydrogenase 1 (ALDH1) has been suggested as a marker of mammary stem cells and prognostic marker [222, 223]. Epithelial and stromal expression of ALDH1 was analysed to assess the probable correlation between ALDH1 and clinicopathological features of breast tumors in a group of Iranian patients. They observed a significant converse correlation between ALDH1 and BRCA1 expressions. Moreover there was a correlation between ALDH1+/BRCA1 low expression phenotype and high grade tumours [224]. BC cases are routinely undergone the different treatments such as surgery, radiotherapy, and chemotherapy. Hormone therapy is also one of the treatment options for the BC cases, in which the tamoxifen targets the positive estrogen receptor tumors through apoptosis induction and ER signaling inhibition [225, 226]. However, it has been observed that a noticeable ratio of tamoxifen treated cases have tumor relapse [227]. PAX2 is one of the members of PAX family of transcription factors which are involved in embryonic development of different organs [228]. PAX2 protein expression was assessed in tamoxifen treated BC patients, and showed that there was a correlation between PAX2 over expression and better survival. Moreover, the tamoxifen responsive cases had significantly higher levels of PAX2 expression compared with tamoxifen resistant patients [229]. MYC is an oncogene involving in various cellular processes, such as cell proliferation and apoptosis [230]. NDRG family is one of the targets of MYC which has four members including NDRG1-4 [231]. NDRG3 has high levels of expression in various tissues including prostate, testis, brain, heart, and kidney [232]. It has been suggested that the NDRG3 has a tumor suppressor role in BC patients, in which the triple negative and advanced stage BC tumors had the lowest levels of NDRG3 expression. Moreover, there was an inverse correlation between NDRG3 expression and survival rate, in which the higher levels of NDRG3 expression resulted in better survival rates among the Iranian BC patients [233].

**Vitamin D and steroids**

Steroid hormones exert their regulatory role on transcription of target genes through binding with steroid receptors including estrogen receptor (ER) and progesterone receptor (PR). ERx has an important function in BC progression through cell growth and proliferation induction. It has been shown that there was an increased expression of ERx in the levels of mRNA and protein in a sub population of Iranian BC tissues in comparison with normal margins and it was associated with tumor size [234]. A mutational analysis has also shown that the presence of the ERx gene A908G mutation among a sub population of Iranian cases with invasive BC. Moreover, they observed a significant correlation between ER-α A908G mutation and familial BC [235]. P450 family is one the most important genes which are involved in steroid hormones metabolism. It has been observed that there was a significant association between rs10,046 polymorphism of CYP19 gene and BC among a group of Iranian patients [236]. TNF-α is involved in estrogen synthesis [237, 238] and down-regulation of ER [239]. Steroid hormone receptor is a prognostic factors to identify sensitive patients for hormone therapy, and also is associated with higher survival rates [240]. It has been shown that there was a significant correlation between TNFA −308 A/G polymorphism and levels of ER expression in a sub population of Iranian BC patients. Moreover, the cases...
harboring TNFA2 and TNFB2 alleles had lower risk of PR positive tumors in comparison with the TNFA1/A1 and TNFB1/B1 homozygous genotypes. They highlighted the correlation between immune and endocrine systems in BC progression, in which higher levels of TNF-α inhibits the PR expression [241]. TNFSF4 is also a glycoprotein belonged to the TNF family which is expressed on activated T cells and various antigen presenting cells such as dendritic cells and B cells [242–244]. It has been shown that the rs3850641 G allele is significantly correlated with an increased risk of BC among Iranian cases [245]. The inverse relation between 25-hydroxyvitamin D serum levels and BC can be related to the apoptotic and antiproliferative roles of vitamin D [246]. VDR is a nuclear receptor for the steroid hormones participating in regulation target genes which are involved in cell proliferation [247, 248]. VDR/RXR complex binds to the promoter sequences of target genes to regulate their expression [249]. The length of VDR poly(A) microsatellite was assessed in a sub population of Iranian BC cases, and showed a significant correlation between increased BC risk and VDR poly(A) L variant [250]. This region is associated with mRNA stability, which highlights the key role of poly(A) microsatellite in regulation of VDR mRNA expression. CYP27B1 is involved in conversion of 25–hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 which finally regulates the transcription of target genes through VDR/RXR complex [251, 252]. This complex regulates the cell growth, apoptosis, and inflammation [253]. Finally the vitamin D pathway is terminated via CYP24A1 [254]. It has been reported that the levels of CYP27B1 mRNA expression in normal was higher than that in the tumor samples. In contrast, the tumors had significantly elevated levels of CYP24A1 expression compared with normal tissues. The CYP24A1 and CYP27B1 were significantly correlated with age and stage, respectively [255]. Another groups have also shown that there was a significant correlation between VDR BsmI polymorphism and elevated BC risk [256, 257]. CYP17 is a steroid monooxygenase which is involved in synthesis of glucocorticoids and sex steroids [258, 259]. It has been shown that the CYP17 MspA1 Polymorphism is probably age specific and is associated with increased risk of early onset BC among Iranian subjects [260].

Cancer testis antigens
Cancer-testis antigens (CTA) are commonly expressed in testis and also with a lower ratio in ovarian germ cells [261]. Tumor cells also express antigens which are restricted to the germ cells. CTAs participate in EMT, self renewal, and tumor invasion [262]. AKAP as a group of CTAs has critical roles in sperm function which exerts their role through the protein kinase A (PKA). The levels of AKAP3 mRNA expression was assessed in tumor compared with normal margins of a sub population of Iranian BC cases, and showed a significant lower expressions in tumors compared with normal tissues. However, there was an inverse correlation between the levels of AKAP3 expressions and tumor sizes and stages, highlighting that as a probable inhibitor of proliferation [263]. WW-binding protein 2 (WBP2) as a CT antigen also regulates the expression of ERS/PR target genes through activation of ERS/PR expression in BC [264]. It has been demonstrated that the WBP2NL is probably associated with cell proliferation in embryonic stem cells and tumor cell lines [265]. WBP2NL over expression was also observed among the Iranian BC patients, highlighting that as a novel prognostic factor [266]. It has been reported that there was a significant correlation between MAGE-1 expression and lymph node involvement, and also between positive nuclear MAGE-1 expression and tumor size among Iranian BC patients [267]. Expressional analysis of TSGA10 CTA was performed in Iranian BC patients and showed its expression in 70% of patients while the only 12% of patients had immune response against TSGA10 [268]. ODF is involved in sperm tail maintenance and centrosome matrix [269] which facilitates the tumor cell proliferation. The RHOXF2 is associated with cell transformation [270] and cell to cell contacts [271]. The ODF4 and RHOXF2 cancer testis antigens had overexpression in tumors compared with normal marines in a sub population of Iranian BC patients [272].

Mitochondrial DNA
Mitochondria as the powerhouse in the cells are involved in redox homeostasis, innate immunity, and apoptosis. Aberrant cellular energetics is one of the most critical risk factors during the tumor progression. Mitochondrial DNA mutations and enzyme defects are the main dysfunctions which cause the cellular energetic problems [273, 274]. The mitochondrial genome encodes various factors of respiratory chain and mitochondrial non coding RNAs [275]. ND4 as one of the respiratory chain components in mitochondria complex I (initiation of electron transport chain) is involved in various cancers [276]. Through the mitochondrial respiratory chain, reactive oxygen species (ROS) are generated due to the electron transfer, therefore it is really important to maintain the production and degradation of ROS, since there is not any protective factor in mitochondrial genome [277]. Mutational analysis of ND4 in a sub population of Iranian BC patients showed that there was a correlation between ND4 alteration and BC [278]. The mtDNA alterations are associated with the increased oxidative stresses and apoptotic resistance [279, 280]. The ATPase6 is belonged to the complex V genes, and contributed to
the preservation of mtDNA [281]. The high frequency of ATPase6 mitochondrial mutations were observed in BC patients and highlighted the importance of mitochondrial gene variants in BC progression through modulation of metabolism, and can be introduced as molecular biomarkers among Iranian BC cases [282].

**Conclusions**

For the first time in the current review we have summarized all of the recent significant genetic markers among Iranian BC patients. It seems that the non-coding RNAs, epigenetic modifications, and immune responses are the most common reported cell and molecular processes which are involved in tumor progression among Iranian BC patients. Moreover, we concluded that there were fifteen out of 117 reported genes which were assessed in higher numbers of BC patients and controls and they can be considered as the main high risk genes among Iranian BC patients (Table 2). Indeed, it is believed that the current review will be useful to pave the way of introducing a population based diagnostic panel markers for the early detection of BC among Iranians. Moreover, current review clarifies the molecular and genetic bases of BC progression in this population.

**Abbreviations**

BC: breast cancer; GSTs: glutathione S-transferases; CYP450: cytochrome 450; HSPs: heat shock proteins; ABC: ATP-binding cassette; AMPK: AMP-activated protein kinase; PDEs: phosphodiesterases; cGMP: cyclic guanosine monophosphate; PKG: Protein Kinase G; ICN: intracellular domain of Notch; CTLa-4: cytotoxic T-lymphocyte antigen-4; TGF: transforming growth factor; HER-2: epidermal growth factor 2; EGF: epidermal growth factor; NRP1: neuropilin-1; IGF-1: insulin-like growth factor 1; CA: cytosine–adenine; PI3K: phosphatidylinositol-3 kinase; S1P: sphingosine-1-phosphate; ER: estrogen receptor; PR: progesterone receptor; miRNA: long non-coding RNAs; HOTAIR: HOX transcript antisense intergenic RNA; ATM: ataxia telangiectasia–mutated; FEN1: flap endonuclease 1; HR: homologues recombination; CTA: cancer-testis antigens; PKA: protein kinase A; WBP2: WW-binding protein 2; ROS: reactive oxygen species; MTHFR: methylenetetrahydrofolate reductase; CSC: cancer stem cells; ALDH: aldehyde dehydrogenase 1; EpCAM: epithelial cell adhesion molecule; SDC1: Syndecan-1.

**Table 2 The most reported and high risk genes among Iranian BC patients**

| Gene   | Number of studies | Number of patients (total) | Number of controls (total) |
|--------|-------------------|-----------------------------|---------------------------|
| CYP2D6 | 2                 | 185                         | –                         |
| FOXO3  | 2                 | 95                          | 80                        |
| LEPTIN | 2                 | 303                         | 271                       |
| TGFβ   | 2                 | 210                         | 210                       |
| HER2   | 3                 | 509                         | 15                        |
| ERBB4  | 3                 | 490                         | 486                       |
| CASP8  | 2                 | 263                         | 203                       |
| PS3    | 2                 | 467                         | 203                       |
| PTEN   | 3                 | 260                         | 70                        |
| VDR    | 3                 | 477                         | 497                       |
| ATM    | 3                 | 298                         | 248                       |
| BRCA1  | 3                 | 259                         | –                         |
| MTHFR  | 2                 | 378                         | 306                       |
| DNMT3  | 2                 | 172                         | 138                       |
| ERα    | 2                 | 169                         | 157                       |

**References**

1. Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757–61.
2. Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac J Cancer Prev. 2016;17(S3):47–52.
3. Mousavi SM, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13(4):383–91.
4. Sharifian A, et al. Burden of Breast Cancer in Iranian Women is Increasing. Asian Pac J Cancer Prev. 2015;16(12):5049–52.
5. Mahdavifar N, et al. Spatial analysis of breast cancer incidence in Iran. Asian Pac J Cancer Prev. 2016;17(S3):59–64.
6. Afsharfard A, et al. Trends in epidemiology, clinical and histopathological characteristics of breast cancer in Iran: results of a 17 year study. Asian Pac J Cancer Prev. 2013;14(11):6905–11.
7. Abdurahman GQ, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol. 2012;2012:915610.
8. Leong SP, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34(10):2308–24.
9. Iqbal J, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73.
10. Welch PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10(7):705–13.
11. Xu X, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22(1):37–43.
12. Sidransky D, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52(10):2984–6.
13. Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7.
14. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell. 2007;11(2):103–5.
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
16. Ryan BM, Robles AJ, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10(6):389–402.
17. Danesh H, et al. Association study of mir-100, mir-124-1, mir-218-2, mir-301b, mir-605, and mir-4295 polymorphisms and the risk of breast cancer in a sample of Iranian population. Gene. 2018;647:73–8.
18. Zhang Y, et al. Estrogen receptor alpha signaling regulates breast tumor-inhibiting cells by down-regulating mir-140 which targets the transcription factor SOX2. J Biol Chem. 2012;287(49):41514–22.
19. Heydari N, et al. Overexpression of serum MicroRNA-140-3p in premenopausal women with newly diagnosed breast cancer. Gene. 2018;655:25–9.
20. Parchami Barjui S, et al. Study of correlation between genetic variations and miR-20a expression in breast cancer patients. Iran Biomed J. 2012;16(2):148–55.
21. Omrani M, et al. Hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014;8(2):259–67.
22. Landi D, et al. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol. 2008;27(11):343–54.
23. Hashemi M, et al. miR-608 rs4919510 C>G polymorphism decreased the risk of breast cancer in an Iranian subpopulation. Exp Oncol. 2016;38(1):57–9.
24. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008;68(19):1816–4.
25. Qi L, et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9:163.
26. Savad S, et al. Expression analysis of Mir-21, Mir-205, and Mir-342 in breast cancer. Iran J Cancer Prev. 2012;5(3):873–7.
27. Zenz T, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16):3801–8.
28. Mansoor B, et al. Micro RNA 34a and Let-7a expression in human breast cancers is associated with apoptotic expression genes. Asian Pac J Cancer Prev. 2015;16(10):4987–90.
29. Saberi A, et al. MiR-328 may be considered as an oncogene in human invasive breast carcinoma. Iran Red Crescent Med J. 2016;18(11):e42360.
30. Damavandi Z, et al. Ablation expression of breast development-related microRNAs, miR-22, miR-132, and miR-212, breast tumor tissues. J Breast Cancer. 2016;19(2):148–55.
31. Ma XP, et al. Association between microRNA polymorphisms and cancer risk based on the findings of 66 case-control studies. PLoS ONE. 2013;8(11):e79584.
32. Nejati-Azar A, Allivand MR. miRNA 196a2(rs11614913) & 196a1(rs2910164) polymorphisms & breast cancer risk for women in an Iranian population. Per Med. 2018;15(4):279–89.
33. Cai Y, He J, Zhang L. Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Oncol Targets Ther. 2015;8:2657–64.
34. Ling H, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23(9):1464–61.
35. Sarrafzadeh S, et al. Expression study and clinical correlations of MYC and CCAT2 in breast cancer patients. Iran Biomed J. 2017;21(5):303–11.
36. Gupta RA, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–6.
37. Hassanzarei S, et al. Genetic polymorphisms of HOTAIR gene are associated with the risk of breast cancer in a sample of southeast Iranian population. Tumour Biol. 2017;39(10):1010483177277539.
38. Zhouravleva G, et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 1995;14(16):4065–72.
39. Hoshino S, et al. Novel function of the eukaryotic polypeptide-chain releasing factor 3 (eRF3/2GSP) in the mRNA degradation pathway. Biochemistry (Moscow). 1999;64(12):1367–72.
40. Hansen LL, Jakobsen C, Justesen J. Assignment of the human peptide chain release factor 3 (GSP2) to Xp11.23-2p11.21 and of the distal marker DXS1039 by radiation hybrid mapping. Cytogenet Cell Genet. 1999;86(3–4):250–1.
41. Ozawa K, et al. Mapping of the human GSP1 gene, a human homolog of the yeast GST1 gene, to chromosomal band 16p11.3. Somat Cell Mol Genet. 1992;18(2):189–94.
42. Miki M, et al. GGCn polymorphism of eRF3a/GSPT1 gene and breast cancer susceptibility. Med Oncol. 2012;29(3):1581–5.
43. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22(22):4632–42.
44. Ueland PM, et al. Clinical and biological implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001;22(4):195–201.
45. Hosseini M, Houhmand M, Ebrahimi A. MTHFR polymorphisms and breast cancer risk. Arch Med Sci. 2011;7(1):134–7.
46. Rezaei H, Rassi H, Mansur FN. Investigation of Methylenetetrahydrofolate reductase C677T polymorphism and human papilloma virus genotypes in Iranian breast cancer. Monoclon Antib Immunodign Immunother. 2017;36(3):124–8.
47. Johansson H, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 2013;4:1715.
48. Jahangiri R, et al. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients. Gene. 2018;685:24–31.
49. Eftekhar E, et al. The study of DNA methyltransferase-3B promoter variant genotype among iranian sporadic breast cancer patients. Iran J Med Sci. 2014;39(3):268–74.
50. Ghavami S, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet. 2009;46(8):497–510.
51. Hashemi M, et al. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8-652 N ins/del promoter polymorphism (rs8341249) in breast cancer. Gene. 2012;505(1):176–9.
52. Aghababaezadeh M, et al. Downregulation of Caspase 8 in a group of Iranian breast cancer patients—a pilot study. J Egypt Natl Canc Inst. 2017;29(4):191–5.
53. Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Hum Mutat. 2003;21(3):321–6.
54. Eskandari-Nasab E, et al. Effect of TP53 16-bp and beta-TrCP 9-bp INS/DEL polymorphisms in relation to risk of breast cancer. Gene. 2015;568(2):191–5.
55. Payandeh M, et al. Expression of p53 breast cancer in kurdish women in the West of Iran: a reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev. 2016;17(3):1261–4.
56. Chipuk JE, et al. The Bcl-2 family reunion. Mol Cell. 2010;37(3):299–310.
57. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 2011;21(1):92–101.
58. Rostamizadeh L, et al. Bcl-2 gene expression in human breast cancers in Iran. Asian Pac J Cancer Prev. 2013;14(7):4209–14.
59. Freeman DJ, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003;3(2):117–30.
60. Li AG, et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575–87.
61. Golmohammadi R, et al. Prognostic role of PTEN gene expression in breast cancer patients from north-east Iran. Asian Pac J Cancer Prev. 2015;16(7):181–5.
62. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264(1):42–55.
66. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366(6458):704–7.

67. Nielsen NH, et al. Methylation of the p16(INK4a) tumor suppressor gene at CpG island in breast cancer. Cancer Lett. 2002;163(1):59–69.

68. Kannan K, et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA. 2003;100(3):1221–5.

69. Malumbres M, et al. Cell cycle control and cancer. Mol Cell Biol. 2000;20(8):2915–25.

70. Vallian S, et al. Methylation status of p16 INK4a tumor suppressor gene in Iranian patients with sporadic breast cancer. J Cancer Res Clin Oncol. 2009;135(8):991–6.

71. Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst. 2000;92(10):795–802.

72. Salmi M, Mozdarani H, Majdzaadeh K. Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients. Med Oncol. 2012;29(3):1502–9.

73. Mehdipour P, et al. Importance of ATM gene as a susceptible trait: preliminary findings. J Cancer Res Ther. 2012;8(3):156–9.

74. Amininia S, et al. Association between CCNE1 polymorphisms and the risk of breast cancer in a sample of Southeast Iranian population. BMC Med Genet. 2017;15:30.

75. Tariq M, et al. Methylation status of p16 INK4A tumor suppressor gene in peripheral blood mononuclear cells of breast cancer patients. Med Oncol. 2014;31(10):189.

76. Yoshihara T, Collado D, Hamaguchi M. Cyclin D1 down-regulation is essential for DBC2’s tumor suppressor function. Biochem Biophys Res Commun. 2007;358(4):1076–9.

77. Siripurapu V, et al. DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J Mol Biol. 2005;346(1):83–93.

78. Hajkhan Mirzaei M, et al. Evaluation of Methylation Status in the 5’UTR Promoter Region of the DBC2 Gene as a Biomarker in Sporadic Breast Cancer. Cell. 2012;14(1):19–24.

79. Golmohammadi R, et al. A single nucleotide polymorphism in codon F311 and V575 of the AURKA gene in invasive ductal breast carcinoma in Middle East. Medicine (Baltimore). 2017;96(37):e7933.

80. Mojgan H, Massoud H, Ahmad E. ERCC1 intron 1 was associated with breast cancer risk. Iran Biomed J. 2012;16(3):325–32.

81. Elliott RL, et al. Human leukocyte antigen G antigen expression in breast cancer: role in immunosuppression. Cancer Biother Radiopharm. 2011;26(2):153–7.

82. Pittillo MP, et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues. Hum Immunol. 2000;61(4):397–407.

83. Salih HR, Nussler V. Commentary: immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res. 2001;6(8):325–32.

84. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest. 2006;24(2):178–86.

85. Elliot RL, et al. Human leukocyte antigen G expression in breast cancer: a case-control study. Br J Cancer. 1997;75(10):1617–20.

86. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.

87. Basu N, et al. Telomerases and telomere dynamics: relevance to cancers of the GI tract. Expert Rev Gastroenterol Hepatol. 2013;7(8):733–48.

88. Vandenbroucke MD, Wellinger RJ. The cell division cycle puts up with unprotected telomerases: cell cycle regulated telomere uncapping as a means to achieve telomere homeostasis. Cell Cycle. 2007;6(10):161–7.

89. Gomez DE, et al. Telomere structure and telomerase in health and disease. Br J Cancer. 2012;107(15):2191–9.

90. Hashemi M, et al. Association between hTERT polymorphisms and the risk of breast cancer in a sample of Southeast Iranian population. BMC Res Notes. 2014;7:895.

91. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J. 1957;1(5022):779–86.

92. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006;34(5):1416–26.

93. Paterson JW. BRCA1: a review of structure and putative functions. Dis Markers. 1998;13(4):261–74.

94. Darbheeshit F, et al. Comparison of BRCA1 expression between triple-negative and luminal breast tumors. Iran J Biomed. 2018;22(3):210–4.

95. Majid Z, et al. BRCA1 protein expression level and CD44+/+phenotype in breast cancer patients. Cell J. 2011;13(3):155–62.

96. Rezaei M, et al. APOBEC3 deletion is associated with breast cancer risk in a sample of southeast Iranian population. Int J Mol Cell Med. 2015;4(2):103–8.

97. Hussain S, et al. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet. 2003;12(19):2503–10.

98. Abbasi S, Roussi M. A rare FANCA gene variation as a breast cancer susceptibility allele in an Iranian population. Mol Med Rep. 2017;56(2):3983–8.

99. Vilgi T, et al. Telomere length and telomerase activity in primary breast cancer and normal breast tissue: a study of 56 patients. Breast Cancer Res Treat. 2006;99(2):141–8.

100. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.
121. Yamashita U, Kuroda E. Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol. 2002;22(2):105–14.

122. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J

124. Dayer R, et al. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis in invasive breast carcinoma: a potent biomarker predicting lymph node metastasis. J Cancer Res Ther. 2018;14(2):345–50.

125. Fontenot JD, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunology. 2005;22(3):329–41.

127. Jaberipour M, et al. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010;16(4):547–51.

128. Hamidinia M, et al. Concomitant Increase of OX40 and FOXP3 transcripts in peripheral blood of patients with breast cancer. Iran J Immunol. 2013;10(1):122–30.

129. Protar M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2013;139(3):627–55.

130. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book. 2013;1:46–51.

131. Pierce BL, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437–44.

132. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007;27(21):3437–44.

133. Guo S, et al. Oncogenic role and therapeutic target of leptin signaling in breast cancer and stem cells. Biochim Biophys Acta. 2012;1825(2):207–22.

134. Rostami S, Kohan L, Mohammadianpanah M. The LEP G-2548A gene polymorphism is associated with age at menarche and breast cancer susceptibility. Gene. 2015;557(2):154–7.

135. Babaei Z, et al. Relationship of obesity with serum concentrations of leptin, CRP and IL-6 in breast cancer survivors. J Egypt Natl Canc Inst. 2015;27(4):223–9.

136. Mohammadzadeh G, et al. The relationship between -2548 G/A Leptin gene polymorphism and risk of breast cancer and serum leptin levels in Ahvazian women. Iran J Cancer Prev. 2015;8(2):100–8.

137. Basu B, et al. D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells. J Biol Chem. 2010;285(35):27026–32.

138. Beauleeu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182–207.

139. Krilova GP, et al. Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J Neurosci Methods. 2008;174(2):272–80.

140. Pommour M, et al. Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer. Asian Pac J Cancer Prev. 2014;15(23):10339–43.

141. Amani D, et al. Transforming growth factor beta1 (TGFbeta1) polymorphisms and breast risk tumour risk. Biol Med Oncol. 2014;35(5):4756–74.

142. Parvizi S, et al. Effects of two common promoter polymorphisms of transforming growth factor-beta1 on breast cancer risks in Ahwaz, west south of Iran. Iran J Cancer Prev. 2016;9(1):5266.

143. Tabatabaei Asaee H, Hojiati Z. Assessment of HER2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry. Gene. 2015;533(1):39–43.

144. Panahi M, et al. Expressional correlation of human epidural growth factor receptor 2, estrogen/progesterone receptor and protein S3 in breast cancer. Asian Pac J Cancer Prev. 2013;14(6):6999–703.

145. Amirniafard N, et al. Relationship between HER2 proto-oncogene status and prognostic factors of breast cancer in the west of Iran. Asian Pac J Cancer Prev. 2016;17(1):295–8.

146. Salmi Z, et al. rs11895168 C allele and the increased risk of breast cancer in Isfahan population. Breast. 2016;28:899–94.

147. Mansouri Bidkani M, et al. ErbB4 receptor polymorphism 2368A>C and risk of breast cancer. Breast. 2018;42:157–63.

148. Bagheri F, et al. Tumor-promoting function of single nucleotide polymorphism rs1836724 (C338TT) alters multiple potential legitimate microRNA binding sites at the 3' untranslated region of ErbB4 in breast cancer. Mol Med Rep. 2016;13(4):4949–8.

149. Normanno N, et al. Epidermal growth factor receptor (EGFR) signalling in cancer. Gene. 2006;366(1)1:16–23.

150. Zhang XM, et al. Expression of tumor related genes NGX6, NAG7, BRD7 in gastric and colorectal cancer. World J Gastroenterol. 2003;9(8):1729–33.

151. Wang L, et al. NGX6 gene inhibits cell proliferation and plays a negative role in EGFR pathway in nasopharyngeal carcinoma cells. J Cell Biochem. 2005;95(1):64–73.

152. Eskandani-Nasarab E, et al. Evaluation of UDP-glucuronyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer. Mol Biol Rep. 2012;39(12):10531–9.

153. Naik A, et al. Neuropilin-1 associated molecules in the blood distinguish poor prognosis breast cancer: a cross-sectional study. Sci Rep. 2017;7(1):3301.

154. Jafari-Alami M, et al. Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues. Cancer Manag Res. 2018;10:1969–74.

155. Cleveland RJ, et al. IGFl CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis. 2006;27(4):758–65.

156. Javad M, Hermanti S, Tavassoli M. Polymorphic CA repeat length in insulin-like growth factor 1 and risk of breast cancer in Iranian women. Med Oncol. 2012;29(2):516–20.

157. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253(1):239–54.

158. Azizi Tabesh G, et al. The high frequency of PIK3CA mutations in iranian breast cancer patients. Cancer Invest. 2017;35(1):36–42.

159. Sanei S, et al. KRAS gene polymorphisms and their impact on breast cancer risk in an Iranian population. Asian Pac J Cancer Prev. 2017;18(5):1301–5.

160. Nazouri AS, et al. High expression of sphingosine kinase 1 in estrogen and progesterone receptors-negative breast cancer. Iran J Pathol. 2017;12(3):218–24.

161. Bunney TD, Katar M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010;10(5):342–52.

162. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008;27(41):5486–96.

163. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497–510.

164. Heshmatpour N, et al. Association between the lengths of G1 dinucleotide repeat in the PIK3CA gene with breast cancer risk. Med Oncol. 2014;31(7):29.

165. Ghulai A, et al. Overexpressed in colorectal carcinoma gene (OCC-1) upregulation and APPL2 gene downregulation in breast cancer specimens. Mol Biol Rep. 2018;45(6):11889–95.

166. Karam-Tehrani F, et al. Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors. Tumour Biol. 2016;37(7):8849–56.

167. Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res. 2003(5)(1):8–15.

168. Nikseresht M, et al. Overexpression of the novel human gene, UBE2Q2, in breast cancer. Cancer Genet Cytogenet. 2010;197(2):101–6.

169. Vogl FD, et al. Glutathione S-transferases M1, T1, and P1 and breast cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2004;13(9):1473–9.

170. Hashemi M, et al. Expression of the PIK3CA gene is associated with worse prognosis breast cancer: a cross-sectional study. Breast Cancer Res. 2014;16(9):1226–32.

171. Sharif MR, et al. Association of GSTO1 A140D and GSTO2 N142D gene variations with breast cancer risk. Asian Pac J Cancer Prev. 2017;18(6):1723–7.
172. Petersen DD, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP Am J Hum Genet. 1991;48(4):720–5.

173. Saadatan H, et al. Polymorphism of the cytochrome P-450 1A1 (A245G) in women with breast cancer in Eastern Azerbaijan, Iran. Iran J Basic Med Sci. 2014;17(3):227–30.

174. Saghafi F, et al. CYP2D6*3 (A2549del), *4 (G1846A), *10 (C1007T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomed Rep. 2018;9(5):446–52.

175. Darakhshan S, et al. Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev. 2013;14(11):6869–74.

176. Motamedi S, et al. Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients. Asian Pac J Cancer Prev. 2012;13(12):6101–4.

177. Meijanto E, Hermaian A, Anindiyayati A. Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev. 2012;13(2):427–36.

178. Lash TL, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst. 2011;103(8):489–500.

179. Yazdi MF, et al. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16(5):6783–7.

180. Ciocca DR, et al. Biological and clinical implications of heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31(3):164–72.

181. Mehlen P, et al. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. Immunol. 1995;154(1):363–74.

182. Calderwood SK, et al. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2000;25:304–10.

183. Homaei-Shandiz F, et al. Anti-heat shock protein-27 antibody levels and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomed Rep. 2018;9(5):446–52.

184. Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability. Expert Opin Drug Metab Toxicol. 2016;12(1):565–77.

185. Ghafouri H, et al. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with breast cancer in women with breast cancer micrometastasis. Asian Pac J Cancer Prev. 2014;15(9):69.

186. Tepass U, et al. Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol. 2000;1(2):91–100.

187. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–90.

188. Sadeghi S, Hojiat Z, Tabatabaieian H. Cooverexpression of EpCAM and c-myc genes in malignant breast tumours. J Genet. 2017;96(1):109–18.

189. Maetzel D, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):162–71.

190. Gottlinger HG, et al. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer. 1986;38(1):47–53.

191. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–90.

192. Sadeghi S, Hojiat Z, Tabatabaieian H. Cooverexpression of EpCAM and c-myc genes in malignant breast tumours. J Genet. 2017;96(1):109–18.

193. Malek-Hosseini Z, et al. Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size. Breast Cancer. 2017;24(6):742–7.

194. Mobasher MB, Shirkoohi R, Modarressi MH. Synaptosomal complex protein 3 transcript analysis in breast cancer. Iran J Public Health. 2016;45(12):1618–24.

195. Zarei F, et al. Higher risk of progressing breast cancer in Kurdish population associated to CDH1 -160 C/A polymorphism. EXCLI J. 2017;16:1198–205.

196. Zarei F, et al. Higher risk of progressing breast cancer in Kurdish population associated to CDH1 -160 C/A polymorphism. EXCLI J. 2017;16:1198–205.

197. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.

198. Esmaili R, et al. Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis. Cancer Cell Int. 2018;18:28.

199. Malek-Hosseini Z, et al. The stromal overexpression of CD10 in invasive breast cancer and its association with clinicopathologic factors. Iran J Cancer Prev. 2014;7(1):17–21.

200. Fridolffson HN, et al. Regulation of intracellular signalling and function by caveolin. FASEB J. 2014;28(9):3823–31.

201. Beavo JA. Cyclic nucleotide phosphodiesterase: functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725–48.

202. Lincoln TM, Cormwell TL. Intracellular cyclic GMP receptor proteins. FASEB J. 1993;7(2):328–38.

203. Karami-Tehrani F, et al. Evaluation of PDEs and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012;43(6):470–50.

204. Fiscus RR, Murad F. cGMP-dependent protein kinase activation in intact tissues. Methods Enzymol. 1988;159:150–9.

205. Karami-Tehrani F, et al. Correlation of Wnt and NOTCH pathways in esophageal squamous cell carcinoma. J Cell Commun Signal. 2016;10(2):129–35.

206. Moghbeli M, et al. Correlation of Wnt and NOTCH pathways in esophageal squamous cell carcinoma. J Cell Commun Signal. 2016;10(2):129–35.

207. Moghbeli M, et al. Role of Wnt signaling pathway in patients with esophageal squamous cell carcinoma. J Gastrointest Cancer. 2015;46(4):365–9.

208. Paryani M, et al. Over-expression of NOTCH1 as a biomarker for invasive breast ductal carcinoma. J Biotechnol. 2016;215:152–63.
222. Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognosis using ALDH1. Cell Stem Cell. 2007;1(5):485–7.

223. Ginestier C, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.

224. Madjd Z, et al. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev. 2012;13(6):2973–8.

225. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 2006;11(6):469–77.

226. Yu FL, Bender W. A proposed mechanism of tamoxifen in breast cancer prevention. Cancer Detect Prev. 2002;26(5):370–5.

227. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43.

228. Eccles MR, et al. PXA genes in development and disease: the role of PXA2 in urogenital tract development. Int J Dev Biol. 2002;46(4):353–44.

229. Jahangiri R, et al. PXA2 expression is correlated with better survival in tamoxifen-treated breast carcinoma patients. Tissue Cell. 2015;82:135–42.

230. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MAPK signalling pathways. Trends Endocrinol Metabol. 2001;12(6):1687–97.

231. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MAPK signalling pathways. Trends Endocrinol Metabol. 2001;12(6):1687–97.

232. Qu X, et al. Characterization and expression of three novel differentiator-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1–2):35–44.

233. Zhao W, et al. Cloning and expression pattern of the human NDRG3 gene. Biochim Biophys Acta. 2001;1519(1–2):134–8.

234. Estiar MA, et al. Gene expression profiles of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1–2):35–44.

235. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MAPK signalling pathways. Trends Endocrinol Metabol. 2001;12(6):1687–97.

236. Estiar MA, et al. Gene expression profiles of three novel differentiation-related genes belong to the human NDRG gene family. Mol Cell Biochem. 2002;229(1–2):35–44.

237. Duncan LJ, Coldham NG, Reed MJ. The interaction of cytokines in regulating enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcription–polymerase chain reaction. J Mol Endocrinol. 2003;31(1):123–32.

238. Haussler MR, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013;92(2):77–98.

239. Horvath HC, et al. The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J Histochem Cytochem. 2010;58(3):277–85.

240. Zhalehjoo N, Shakiba Y, Panjehpour M. Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues. Mol Med Rep. 2017;15(1):467–73.

241. Shahabi A, et al. Vitamin D receptor gene polymorphism: association with susceptibility to early-onset breast cancer in Iranian, BRCA1/2-mutation carrier and non-cancer patients. Pathol Oncol Res. 2018;24(5):601–7.

242. Shahbazi S, et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393.

243. Reid AH, et al. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5(11):610–20.

244. Setiawan WJ, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2007;16(11):2237–46.

245. Ebrahimi E, et al. CYP17MspA1 gene polymorphism and breast cancer patients according to age of onset in cancer institute of Iran. Iran J Public Health. 2017;46(6):537–44.

246. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;81.

247. Salimannejad A, et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers. Immunol Invest. 2016;45(7):619–40.

248. Eismaeli R, et al. AKAP3 correlates with triple negative status and disease free survival in breast cancer. BMC Cancer. 2015;15:681.

249. Eljamel, et al. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 is associated with breast cancer risk. Mol Cancer. 2014;13:256–64.

250. Nourashrafeddin S, et al. Elevated expression of the testis-specific gene WW-domain binding protein, PEPP2NL in breast cancer. Biomark Cancer. 2015;7:19–24.

251. Askari S, et al. Expression analysis of PAWP during mouse embryonic stem cell-based spermatogenesis in vitro. Vitro Cell Dev Biol Anim. 2014;50(5):475–81.

252. Rastgoosalami M, et al. Evaluation of MAGE-1 cancer/testis antigen expression in invasive breast cancer and its correlation with prognostic factors. Iran J Cancer Prev. 2016;9(4):e4404.

253. Kazemi-Oula G, et al. Upregulation of RHOXF2 and ODF4 expression in breast cancer tissues from the Iranian population—a pilot study. Asian Pac J Cancer Prev. 2014;15(20):8789–91.

254. Abbasi S, et al. Association of estrogen receptor-alpha A908G (K030R) mutation with breast cancer risk. Int J Clin Exp Med. 2013;6(1):39–49.

255. Farzaneh F, et al. Analysis of CYP17, CYP19 and CYP1A1 Gene polymorphisms in Iranian women with breast cancer. Asian Pac J Cancer Prev. 2016;17(5):233–6.

256. Duncan LJ, Coldham NG, Reed MJ. The interaction of cytokines in regulating oestrioid 17 beta-hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol. 1994;49(1):63–8.

257. Newman SP, et al. Regulation of steroid sulphatase expression and activity in breast cancer. J Steroid Biochem Mol Biol. 2000;75(4–5):259–64.

258. Danforth DN, Sgagias MK. Tumour necrosis factor-alpha modulates oestriolid responsiveness of MCF-7 breast cancer cells in vitro. J Endocrinol. 1993;138(3):517–28.

259. Roodi N, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst. 1995;87(6):446–51.

260. Kamali-Sarvestani E, et al. Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients. Pathol Oncol Res. 2005;11(2):99–102.

261. Di C, et al. Basophil-associated OX40 ligand participates in the initiation of Th2 responses during airway inflammation. J Biol Chem. 2015;290(20):12523–36.

262. Lee J, et al. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology. 2008;125(2):229–40.

263. Oshimia M, et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159(8):3838–48.

264. Vakil R, Mashayekhi F: OX40L gene polymorphism and breast cancer in Iranian population. Exp Oncol. 2018;40(2):132–5.

265. Crew KD. Vitamin d: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol. 2013;2013:483687.

266. Jurutka PW, et al. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2(2):203–16.

267. Thorne J, Campbell MJ. The vitamin D receptor in cancer. Proc Nutr Soc. 2008;67(2):115–27.

268. Barsony J, Prufer K. Vitamin D receptor and retinoid X receptor interactions in motion. Vitam Horm. 2002;65:345–76.

269. Colagro AH, Froujzah HM, Halakhor S. Vitamin D Receptor Poly(A) Microsatellite Polymorphism and 25-Hydroxyvitamin D Serum Levels: association with Susceptibility to Breast Cancer. J Breast Cancer. 2015;18(2):119–25.

270. Anderson MG, et al. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 2006;57(2):234–40.

271. Anderson PH, et al. Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcription–polymerase chain reaction. J Mol Endocrinol. 2003;31(1):123–32.
275. Yadav N, Chandra D. Mitochondrial DNA mutations and breast tumorigenesis. Biochim Biophys Acta. 2013;1836(2):336–44.
276. Damm F, et al. Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia. 2012;26(2):289–95.
277. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 2008;18(4):165–73.
278. Arezi P, Rezvani Z. The variation of mitochondrial NADH dehydrogenase subunit 4 (mtND4) and molecular dynamics simulation of SNPs among Iranian women with breast cancer. J Mol Graph Model. 2018;85:242–9.
279. Czarnecka AM, et al. Mitochondrial DNA mutations in cancer—from bench to bedside. Front Biosci (Landmark Ed). 2010;15:437–60.
280. Park JS, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet. 2009;18(9):1578–89.
281. Jonckheere AI, Smeitink JA, Rodenburg RJ. Mitochondrial ATP synthase: architecture, function and pathology. J Inherit Metab Dis. 2012;35(2):211–25.
282. Ghaffarpour M, et al. The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients. Cancer Cell Int. 2014;14(1):21.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.